Objective: To assess evidence regarding periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. The complete guideline on which this summary is based is available as an online data supplement to this article.
must weigh bleeding risks from drug continuation against thromboembolic risks from discontinuation. Stroke patients undergoing dental procedures should routinely continue aspirin (Level A). Stroke patients undergoing invasive ocular anesthesia, cataract surgery, dermatologic procedures, transrectal ultrasound-guided prostate biopsy, spinal/epidural procedures, and carpal tunnel surgery should probably continue aspirin (Level B). Some stroke patients undergoing vitreoretinal surgery, EMG, transbronchial lung biopsy, colonoscopic polypectomy, upper endoscopy and biopsy/ sphincterotomy, and abdominal ultrasound-guided biopsies should possibly continue aspirin (Level C). Stroke patients requiring warfarin should routinely continue it when undergoing dental procedures (Level A) and probably continue it for dermatologic procedures (Level B). Some patients undergoing EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein should possibly continue warfarin (Level C). Whereas neurologists should counsel that warfarin probably does not increase clinically important bleeding with ocular anesthesia (Level B), other ophthalmologic studies lack the statistical precision to make recommendations (Level U). Neurologists should counsel that warfarin might increase bleeding with colonoscopic polypectomy (Level C). There is insufficient evidence to support or refute periprocedural heparin bridging therapy to reduce thromboembolic events in chronically anticoagulated patients (Level U). Neurologists should counsel that bridging therapy is probably associated with increased bleeding risks as compared with warfarin cessation (Level B). The risk difference as compared with continuing warfarin is unknown (Level U). Neurology â 2013;80:2065-2069 GLOSSARY AC 5 anticoagulation; AP 5 antiplatelet; RR 5 relative risk; TE 5 thromboembolic.
Neurologists are frequently asked to recommend whether practitioners should temporarily stop anticoagulation (AC) and antiplatelet (AP) agents in patients with prior strokes or TIAs undergoing invasive procedures. The balance of risks of recurrent vascular events with discontinuation of these agents vs increased periprocedural bleeding with continuation is often unclear, leading to variability in care and possibly adverse outcomes.
This article summarizes the findings, conclusions, and recommendations of an evidence-based guideline regarding periprocedural management of patients with a history of ischemic cerebrovascular disease receiving AC or AP agents. The full text of the guideline is available as a data supplement on the Neurology ® Web site at www.neurology.org. Four questions are addressed:
1. What is the thromboembolic (TE) risk of temporarily discontinuing an antithrombotic medication? 2. What are the perioperative bleeding risks of continuing antithrombotic agents? 3. If oral AC is stopped, should bridging therapy be used? 4. If an antithrombotic agent is stopped, what should be the timing of discontinuation?
DESCRIPTION OF THE ANALYTIC PROCESS The American Academy of Neurology Guideline Development Subcommittee (see appendices e-1 and e-2) convened an expert panel to develop the guideline. Literature searches of MEDLINE and EMBASE through August 2011 were performed (see appendices e-3 and e-4). The searches identified 5,904 citations yielding 133 relevant articles, which were rated for their risk of bias (see appendix e-5), and recommendations were made that were linked to the evidence (see appendix e-6). Articles were included if they studied patients taking oral antithrombotic agents for primary or secondary cardiovascular disease or stroke prevention (including articles relating to atrial fibrillation), studied at least 20 subjects, included a comparison group, assessed risks of continuing or discontinuing an agent, and clearly described interventions and outcome measures. Cardiovascular and cerebrovascular procedures were excluded because of confounding issues. Bleeding was classified according to GUSTO criteria. 1 Moderate or severe bleeding was considered clinically important. All studies are presented in the evidence table (table e-1), including Class III studies that did not inform recommendations.
ANALYSIS OF EVIDENCE What is the TE risk of temporarily discontinuing AP agents? Based on one Class I study 1 and 2 Class II studies 2,3 that addressed TE risks of temporarily discontinuing AP agents, aspirin discontinuation is probably associated with increased stroke or TIA risk. Estimated stroke risk varies with the duration of aspirin discontinuation: relative risk (RR) was 1.97 for 2 weeks, odds ratio was 3.4 for 4 weeks, and RR was 1.40 for 5 months (one Class II study each).
What is the TE risk of temporarily discontinuing AC? Studies of AC discontinuation enroll subjects with various AC indications, each with different TE risks. No studies meeting inclusion criteria with sufficient sample size to support conclusions compared TE risks in subjects continuing warfarin with those discontinuing warfarin (with or without periprocedural heparin bridging). One Class I study 4 found that the TE event risk of warfarin discontinuation is probably higher if AC is stopped for $7 days (RR 5.5, 95% confidence interval 1.2-24.2) (one Class I study).
What are the perioperative bleeding risks of continuing antithrombotic agents? Table 1 summarizes the evidencebased conclusions developed from the systematic review of the literature. Only procedures for which we found evidence appear in table 1. For specific details, including quantitative descriptions of risks, refer to the full guideline document (www.neurology.org).
If oral AC is stopped, should bridging therapy be used?
There is insufficient evidence to support or refute a difference in TE events when heparin bridging is used (vs discontinuation of oral AC without bridging); however, most studies suggest that heparin bridging is probably associated with an increased risk of periprocedural bleeding in general (2 Class I studies, one Class II study, and one Class III study showing increased risk, with one additional Class I study showing no substantial increased risk).
There is insufficient evidence to support or refute differences in TE risk between management strategies of continuing oral AC vs heparin bridging. One Class I study found that the risk of bleeding is probably similar between low-molecular-weight heparin bridging and AC continuation in dental procedures.
If an antithrombotic agent is stopped, what should be the timing of discontinuation? Data are insufficient to support any conclusions.
CLINICAL CONTEXT The antithrombotic effect duration of aspirin and clopidogrel is estimated to be 7 days. 5 The duration of action of a single dose of warfarin is estimated at 2 to 5 days. 5 Hence, to reverse the antithrombotic effect, it is generally recommended that AP agents be stopped 7 to 10 days, and warfarin 5 days, preprocedure. 6 Shorter discontinuation periods were used in many of the reviewed studies.
Stopping antithrombotics increases the risk of TE events. The exact magnitude of this risk increase is unknown. To minimize this risk, it seems reasonable to minimize the duration of antithrombotic discontinuation.
When considering the risks and benefits of antithrombotic discontinuation, it is important to consider both the frequency of undesirable outcomes and their long-term consequences. TE events occur infrequently, but the associated morbidity and mortality rates are high. In contrast, most reported bleeding outcomes are relatively mild. Decisions regarding periprocedural antithrombotic therapy depend on weighing these competing risks in the context of individual patient characteristics.
Patient preferences must inform these risk-benefit judgments. In a study comparing preferences of patients with atrial fibrillation with those of physicians, patients were willing to experience a mean of 17.4 excess-bleeding events with warfarin and 14.7 excess-bleeding events with aspirin to prevent a stroke. 7 Sample clinical scenarios for guideline application are presented in appendix 1. RECOMMENDATIONS 1. It is axiomatic that clinicians managing antithrombotic medications periprocedurally weigh bleeding risks from drug continuation against TE risks from discontinuation at the individual patient level, although high-quality evidence on which to base this decision is often unavailable. In addition, even when evidence is insufficient to exclude a difference in bleeding or shows a small increase in clinically important bleeding with antithrombotic agents, physicians may reasonably judge that the risks and morbidity of TE events exceed those associated with bleeding. 2. Neurologists should counsel both patients taking aspirin for secondary stroke prevention and their physicians that aspirin discontinuation is probably associated with increased stroke and TIA risk (Level B polypectomy, upper endoscopy with biopsy, sphincterotomy, and abdominal ultrasound-guided biopsies. Given the weaker data supporting minimal clinically important bleeding risks, it is reasonable that some stroke patients undergoing these procedures should possibly continue aspirin (Level C). 7. Although bleeding events were rare, studies of transurethral resection of the prostate lack the statistical precision to exclude clinically important bleeding risks with aspirin continuation (Level U). 8. Patients taking aspirin should be counseled that aspirin probably increases bleeding risks during orthopedic hip procedures (Level B). 9. Neurologists should counsel patients that there is insufficient evidence to make recommendations regarding appropriate periprocedural clopidogrel, ticlopidine, or aspirin/dipyridamole management in most situations (Level U). Aspirin recommendations cannot be extrapolated with certainty to other AP agents. 10. Patients taking warfarin should be counseled that warfarin continuation is highly unlikely to be associated with increased clinically important bleeding complications with dental procedures (Level A). Given minimal bleeding risks, stroke patients undergoing dental procedures should routinely continue warfarin (Level A). 11. Patients taking warfarin should be counseled that warfarin continuation is probably associated with only a small (1.2%) increased risk difference for bleeding during dermatologic procedures on the basis of a meta-analysis of heterogeneous and conflicting studies (Level B). Thus, patients undergoing dermatologic procedures should probably continue warfarin (Level B). 12. Patients taking warfarin should be counseled that warfarin continuation is probably not associated with an increased risk of clinically important bleeding with ocular anesthesia (Level B). However, AC practices during ophthalmologic procedures may be driven by the postanesthesia procedure. Although bleeding events were rare, ophthalmologic studies (other than those regarding ocular anesthesia) lack the statistical precision to exclude clinically important bleeding risks with warfarin continuation. Thus, there is insufficient evidence to make practice recommendations regarding warfarin discontinuation in ophthalmologic procedures (Level U). 13. Warfarin might be associated with no increased clinically important bleeding with EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein. Thus, patients undergoing these procedures should possibly continue warfarin (Level C).
14. Patients taking warfarin should be counseled that warfarin continuation might increase bleeding with colonoscopic polypectomy (Level C). Thus, patients undergoing this procedure should possibly temporarily discontinue warfarin (Level C). 15. Neurologists should counsel patients that there is insufficient evidence to make recommendations regarding appropriate periprocedural management of nonwarfarin oral AC (Level U). Warfarin recommendations cannot be extrapolated with certainty to other AC agents. 16. There is insufficient evidence to determine differences in TE in chronically anticoagulated patients managed with heparin bridging therapy relative to oral AC discontinuation or continuation. Patients taking warfarin should be counseled that bridging therapy is probably associated with increased bleeding risks in procedures in general relative to AC cessation (Level B). Bridging probably does not reduce clinically important bleeding relative to continued AC with warfarin in dentistry, but bleeding risk differences between patients managed with continued warfarin vs bridging therapy in other procedures are unknown. Given that the benefits of bridging therapy are not established and that bridging is probably associated with increased bleeding risks, there is insufficient evidence to support or refute bridging therapy use in general (Level U).
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APPENDIX 1
Sample clinical scenarios for guideline application. Clinical scenario 1: Patient A is a 65-year-old man with a history of hypertension and hypercholesterolemia who had a stroke 1 year ago attributed to intracranial large-artery atherosclerosis. He has mild residual left hemiparesis, and his secondary stroke prevention therapy includes risk factor control and aspirin 325 mg daily. He is due for routine colonoscopy screening. His neurologist reviews the guideline and assesses that the patient's risk for recurrent stroke includes his known intracranial large-artery atherosclerotic event. Given that the patient may not need polypectomy with his colonoscopy, that the risk difference for bleeding with polypectomy associated with aspirin is approximately 2.0%, and that bleeding with polypectomy is likely to have lower morbidity risk than recurrent stroke risk, the neurologist recommends that aspirin be continued pericolonoscopy and obtains the opinions of both the patient and his gastrointestinal physician. The patient wants to have his colonoscopy, as his cousin was recently diagnosed with colon cancer, and is willing to accept an increased bleeding risk to avoid recurrent stroke. Thus, he proceeds with colonoscopy and possible polypectomy while continuing aspirin 325 mg daily. Clinical scenario 2: Patient B is a 70-year-old woman who had a small-vessel distribution ischemic stroke associated with uncontrolled hypertension 5 years previously. She has no residual deficits and has been diligent in controlling her vascular risk factors. She has recently been diagnosed with breast cancer requiring mastectomy. Her neurologist reviews the guideline and notes that there is minimal literature for the risks associated with more invasive procedures. The neurologist counsels the patient and her oncologist that the patient likely has a relatively low risk of recurrent stroke with brief aspirin cessation and that there is little research on bleeding risks with aspirin during invasive procedures. Together, they choose to stop the aspirin 7 days before the surgery and restart it the day after the surgery. The importance of restarting the aspirin postoperatively is stressed, and a specific start date is provided to the patient. Clinical scenario 3: Patient C is a 60-year-old man with chronic atrial fibrillation and prior cardioembolic stroke treated with chronic warfarin. He is the primary caregiver for his wife with Alzheimer disease, but his cataracts have worsened to the degree that surgery is needed for him to continue to care for her and drive her to appointments. The patient's neurologist reviews the guideline and finds that the risks associated with warfarin during ophthalmologic procedures have not been established with sufficient precision. The patient feels strongly, however, that he would rather tolerate the chance of increased bleeding complications than risk a recurrent cardioembolic stroke that might impair his ability to care for his wife. Given the risk-benefit ratio and patient preference, the ophthalmologist, neurologist, and patient decide to continue warfarin during the cataract surgery.
